

Karo Pharma acquires brand portfolio from Teva Pharmaceuticals

06 April 2021 | News

The transaction transfers ownership of the brand portfolio, comprised of Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to Karo



Karo Pharma Aktiebolag announces that the acquisition of the European OTC brand portfolio from [Teva Pharmaceuticals](#) (Teva) for 84 MEUR. The agreement was signed and announced earlier on 3 February 2021.

The transaction transfers ownership of the brand portfolio, comprised of Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to Karo.

Karo and Teva have had a close and seamless collaboration since the signing of the agreement leading up to the closing according to plan.

Karo Pharma delivers smart choices for everyday healthcare, including commercializing branded, original over-the-counter products and prescription medicines in more than 60 countries. Europe and the Nordic region are Karo Pharma's core markets. Karo Pharma is headquartered in Stockholm, Sweden.